GlassScriptPhysician profile
Agata Wojtasiewicz
NPI 1376798520
$5,059.11
in general payments reported to CMS, 2019-2025
36 companies · $1,287 in 2025
The $1,287 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $14.58 · 2022: $1,188 · 2023: $1,339 · 2024: $1,231 · 2025: $1,287.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,856.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,856.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $736.03 | 2022-2025 | Vraylar, Ubrelvy, Qulipta |
| Glaxosmithkline, LLC. | $591.91 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $511.93 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $455.13 | 2022-2025 | Jardiance, Mounjaro, Zepbound |
| Pfizer INC. | $241.25 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $217.84 | 2022-2024 | Spravato, Xarelto |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $191.64 | 2025 | Caplyta |
| Shield Therapeutics INC | $176.92 | 2023-2025 | Accrufer |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $158.18 | 2022-2024 | Xifaxan, Trulance |
| Biohaven Pharmaceutical Holding Company LTD. | $151.21 | 2022 | |
| Amgen INC. | $143.84 | 2022-2025 | Repatha, Otezla, Prolia |
| Madrigal Pharmaceuticals | $139.25 | 2025 | Rezdiffra |
| Astrazeneca Pharmaceuticals LP | $137.77 | 2023-2025 | Airsupra, Breztri, Farxiga |
| Merck Sharp & Dohme LLC | $137.27 | 2022-2025 | Gardasil 9, Capvaxive, Gardasil |
| Takeda Pharmaceuticals U.S.A., INC. | $118.05 | 2022-2023 | Trintellix |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $94.02 | 2024 | Voquezna |
| Idorsia Pharmaceuticals US INC | $85.07 | 2022-2023 | Quviviq |
| Exact Sciences Corporation | $78.51 | 2023-2024 | Cologuard Collection Kit |
| Kyowa Kirin, INC. | $78.40 | 2024 | Crysvita |
| Boehringer Ingelheim Pharmaceuticals, INC. | $73.02 | 2022 | |
| Edwards Lifesciences Corporation | $67.44 | 2024-2025 | Sapien 3 Ultra Resilia |
| Bayer Healthcare Pharmaceuticals INC. | $55.73 | 2022-2023 | |
| Astellas Pharma US INC | $53.32 | 2024-2025 | Veozah |
| E.R. Squibb & Sons, L.L.C. | $49.24 | 2022-2023 | |
| Corcept Therapeutics | $40.73 | 2025 | Korlym |
| Bausch Health US, LLC | $36.49 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $35.46 | 2024 | Rexulti |
| Tactile Systems Technology INC | $33.00 | 2025 | Flexitouch Plus, Nimbl |
| Corium, LLC | $29.48 | 2023 | Azstarys |
| Teva Pharmaceuticals USA, INC. | $29.35 | 2022 | |
| Alk-Abello, INC | $24.81 | 2024 | Ragwitek, Grastek, Odactra |
| Gilead Sciences, INC. | $20.38 | 2024 | |
| Amarin Pharma, INC. | $18.78 | 2022 | |
| Axsome Therapeutics, INC. | $17.23 | 2023 | Auvelity |
| Ibsa Pharma INC. | $15.87 | 2023 | Tirosint, Licart |
| Lundbeck LLC | $14.56 | 2024 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Agata Wojtasiewicz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.